Erlotinib intermediates manufacturer
Enzalutamide, is a nonsteroidal antiandrogen (NSAA) which is used for the treatment of metastatic, castration-resistant prostate cancer (CRPC). An up to 89% decrease in serum prostate specific antigen (PSA) levels have been reported after a month of taking the drug. Research suggests that enzalutamide may also be effective in the treatment of certain types of breast cancer. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of CRPC.
| Product Name: | Enzalutamide (MDV3100) |
| Synonyms: | MDV-3100;4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide;4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide;4-{3-[4-cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-sulfanylideneiMidazolidin-1-yl}-2-fluoro-N-MethylbenzaMide;EnzalutaMide;MDV3100 (EnzalutaMide);MDV 3100,4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluoro-N-MethylbenzaMide;4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N |
| CAS: | 915087-33-1 |
| MF: | C21H16F4N4O2S |
| MW: | 464.4359528 |
| EINECS: | 805-022-1 |
| Product Categories: | Apoptosis;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Inhibitor |
| Mol File: | 915087-33-1.mol |
| Appearance | white powder |
| MOQ | 1g |
COA of Enzalutamide
| Item | Specification |
| Specific rotation | +39.5 to +41.5° |
| State of solution(transmittance) | Clear 98.0% min. |
| Chloride[cl] | 0.020% max. |
| Ammonium [NH4] | 0.02% max. |
| Sulfate[SO4] | 0.020% max |
| Iron[Fe] | 10ppm max. |
| Heavy metals [Pb] | 10ppm max |
| Arsenic[As2O3] | 1ppm max |
| Other amino acids | Chromatographically not detectable |
| Loss on drying | 0.20% max. |
| Residue on ignition[sulfated] | 0.10% max. |
| Assay | 99.0% min |
HS CODE: 29339900
